AstraZeneca Manuals

AstraZeneca Daclatasvir Hydrochloride Tablets (DAKLINZATM) Product Leaflet

The Daclatasvir Hydrochloride Tablets (DAKLINZATM) are indicated for the treatment of adult chronic hepatitis C virus (HCV) infection in combination with other antiviral agents. The recommended dosage is 60 mg taken orally once daily, with or without food. The tablet is a shallow‑green, biconvex, five‑sided film‑coated tablet marked with “BMS” on one side and “215” on the other.

The leaflet provides detailed safety information, including contraindications (e.g., hypersensitivity, co‑administration with strong CYP3A4 inducers), common adverse reactions such as headache (14 %) and fatigue (11 %), and guidance for special populations (renal or hepatic impairment, elderly, pregnancy). Storage conditions, packaging details, and the manufacturer’s contact information are also included. This manual is written in Chinese.

Covers: Indications · Dosage and Administration · Contraindications · Warnings and Precautions · Adverse Reactions · Pharmacokinetics